Infant Bacterial Therapeutics
54,8
SEK
-7,12 %
IBT B
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Vær den første som følger denne virksomhed
-7,12%
+43,46%
+57,02%
-44,42%
-39,11%
-39,25%
-10,16%
-60,4%
-6,27%
Infant Bacterial Therapeutics, also known by the name IBT, is a pharmaceutical company. The company develops drugs to treat and prevent children from developing common ailments and diseases that occur at premature birth. Common is that disorders can occur in the development of microorganisms such as microbiome. The largest operations are in the Nordic market. The company's head office is located in Stockholm.
Læs mereMarkedsværdi
738,23 mio. SEK
Aktieomsætning
1,88 mio. SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Finanskalender
13.2
2025
Årsrapport '24
7.5
2025
Delårsrapport Q1'25
8.5
2025
Generalforsamling '24
ViserAlle indholdstyper
Infant Bacterial Therapeutics AB (publ) Interim report January 1 – September 30, 2024
Infant Bacterial Therapeutics to present at FDA workshop in the USA
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools